FDA Accepts Kabi’s Actemra Biosimilar – Will It Be First?
German Firm Plans Both US And EU Launches In 2023
Fresenius Kabi has been tipped to strike first in the race to launch a biosimilar to Actemra – a market where competition “is likely to be thin for some time.”
You may also be interested in...
Celltrion has provided the latest update on progress for its CT-P47 proposed tocilizumab biosimilar, with Phase III trials set to begin for its rival to Actemra/RoActemra.
Biogen and Bio-Thera have revealed positive Phase III data for their proposed tocilizumab biosimilar rival to Actemra/RoAcetmra.
Theramex and Enzene have struck a deal to commercialize a tocilizumab biosimilar rival to Roche’s RoActemra in Europe – including the UK and Switzerland – as well as Australia. The two companies recently partnered for Enzene’s proposed biosimilar version of Prolia (denosumab).